The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
Open accessAbstract
Purpose: Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without cetuximab in this setting. Patients and Methods: Patients who had received no more than one previous chemotherapy regimen were randomly assigned on a 2:1 schedule to receive no more than six cycles of cisplatin plus cetuximab or cisplatin alone. Patients receiving cisplatin alone could switch to cisplatin plus cetuximab or cetuximab alone on disease progression. The primary end point was overall response rate (ORR). Secondary end points studied included progression-free survival (PFS), overall survival (OS), and safety profiles. Analyses included a significance level of α = .10 with no adjustments for multiplicity. Results: The full analysis set comprised 115 patients receiving cisplatin plus cetuximab and 58 receiving cisplatin alone; 31 patients whose disease progressed on cisplatin alone switched to cetuximab-containing therapy. The ORR was 20% (95% CI, 13 to 29) with cisplatin plus cetuximab and 10% (95% CI, 4 to 21) with cisplatin alone (odds ratio, 2.13; 95% CI, 0.81 to 5.59; P = .11). Cisplatin plus cetuximab resulted in longer PFS compared with cisplatin alone (median, 3.7 v 1.5 months; hazard ratio [HR], 0.67; 95% CI, 0.47 to 0.97; P = .032). Corresponding median OS was 12.9 versus 9.4 months (HR, 0.82; 95% CI, 0.56 to 1.20; P = .31). Common grade 3/4 adverse events included acne-like rash, neutropenia, and fatigue. Conclusion: While the primary study end point was not met, adding cetuximab to cisplatin doubled the ORR and appeared to prolong PFS and OS, warranting further investigation in mTNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Self-citationPirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Self-citationEfficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Jiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
Self-citationCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Self-citationVoorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Triple negative breast cancer: Pitfalls and progress
Zagami, P., & Carey, L. A. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00468-0 · Cited by 839
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Self-citationLehmann, B. D., & Pietenpol, J. A. (2014) · The Journal of Pathology · doi:10.1002/path.4280 · Cited by 495
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Recent Advances in the Treatment of Breast Cancer
Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00227 · Cited by 399
Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0797-x · Cited by 390
Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 382
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 333
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 317
O'Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., Robert, N., Hellerstedt, B., Saleh, M., Richards, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2984 · Cited by 311
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., Kim, I. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.251 · Cited by 300
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
PARP inhibitors in the management of breast cancer: current data and future prospects
Livraghi, L., & Garber, J. E. (2015) · BMC Medicine · doi:10.1186/s12916-015-0425-1 · Cited by 269
Genetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 262
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Gu, G., Dustin, D., & Fuqua, S. A. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.11.005 · Cited by 163
Guestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
Zhang, W., Xia, D., Li, Z., Zhou, T., Chen, T., Wu, Z., Zhou, W., Li, Z., Li, L., & Xu, J. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1855-z · Cited by 38
Upreti, M., Jyoti, A., Johnson, S. E., Swindell, E. P., Napier, D., Sethi, P., Chan, R., Feddock, J. M., Weiss, H. L., O’Halloran, T. V., et al. (2106) · Oncotarget · doi:10.18632/oncotarget.9490 · Cited by 21
“An improved understanding of the biology of TNBC has led to the discovery of therapeutic targets for TNBC, such as the Notch signaling pathway (RO-4929097) [10], Wnt/b-catenin pathway (Salinomycin) [11], DNA repair pathways (PARP1 inhibitors: Iniparib, Olaparib) [12, 13], Overexpressed epidermal growth factor (EGFR in…”
Background
Metadata
- Authors
- Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J.-C., Graas, M.-P., Kennedy, M. J., Ciruelos Gil, E. M., Schneeweiss, A., Zubel, A., Groos, J., Melezínková, H., & Awada, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-07-10
- Volume
- 31
- Issue
- 20
- Pages
- 2586-2592
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104024752
- Cited by
- 363
- References
- 30
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.